On the bright side, there were no significant adverse events as a result of Optune treatment, even though the patients who received it had more advanced cases of the disease than historical controls. And while the percentage of patients who either had no worsening of their disease or at least partial improvement (called "disease control rate") was better with Novocure's treatment (76% versus 40%-50% for historical controls), it was less than Wall Street was hoping.